[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"olfactory-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:olfactory-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,84,108,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100530811","sinus-disease-in-young-children-with-cystic-fibrosis-100530811",false,"NCT06191640","Sinus Disease in Young Children With Cystic Fibrosis","Inclusion Criteria:\n\nHEMT Group:\n\n* Children with documentation of a CF diagnosis\n* Age 2-8 years old at first study visit\n* CFTR mutation consistent with FDA labeled indication of highly effective modulator therapy (ivacaftor or elexacaftor\u002Ftezacaftor\u002Fivacaftor)\n* Clinician intent to prescribe ivacaftor or ETI so that enrollment is before start of HEMT\n\nNon-HEMT\u002FControl Group:\n\n* Children with documentation of a CF diagnosis\n* Age 2-8 years at first study visit\n* Ineligible for highly effective modulator therapy (ivacaftor or elexacaftor\u002Ftezacaftor\u002Fivacaftor) based on CFTR mutation or clinical decision not to initiate HEMT if eligible\n\nExclusion Criteria:\n\nFor Both Groups:\n\n* Use of an investigational drug within 28 days prior to the first study visit\n* Use of ivacaftor or elexacaftor\u002Ftezacaftor\u002Fivacaftor within the 180 days prior to and including the first study visit\n* Use of chronic oral corticosteroids within the 28 days prior to and including the first study visit.\n* Sinus surgery within 180 days prior to the first study visit","ALL","2 Years","8 Years",{"count":19,"type":20},80,"ESTIMATED","OBSERVATIONAL","This is a prospective, observational study examining the impact of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators on chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) in young children with cystic fibrosis (YCwCF). This study involves two groups: children 2-8 years old, inclusive at initial visit, receiving highly effective modulator therapy (HEMT), and a control group of children 2-8 years old, inclusive at initial visit, not receiving HEMT. Outcomes will include sinus magnetic resonance imaging (MRI) scans, olfactory tests, and quality of life surveys obtained over a two-year period.",[24,25,26,27,28],"Cystic Fibrosis in Children","Cystic Fibrosis","Chronic Rhinosinusitis (Diagnosis)","Olfactory Disorder","Olfactory Impairment",[25,30,31],"Chronic Rhinosinusitis","Olfactory Dysfunction","RECRUITING","2026-05-06",{"date":35,"type":36},"2026-05-11","ACTUAL",{"date":38,"type":36},"2023-04-12",{"date":40,"type":20},"2029-06-30",{"name":42,"class":43},"University of California, Los Angeles","OTHER",6,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100504979","phase-2-study-of-chemosensory-enhancement-through-neuromodulation-training-scent-for-long-covid-100504979","NCT05855369","Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)","A Randomized Controlled Trial of Smell Training and Trigeminal Nerve Stimulation in the Treatment of COVID-related Persistent Smell Loss","Inclusion Criteria:\n\n* treatment-seeking for COVID-related persistent SL (anosmia, hyposmia, phantosmia or parosmia)\n* at least 1-month from SARS-coV-2 PCR-positive and\u002For rapid home-positive tests\n* normal sense of smell prior to COVID\n* naïve to both smell training (ST) and trigeminal nerve stimulation (TNS)\n* able to comprehend English and provide informed consent\n\nExclusion Criteria:\n\n* history of head injury (e.g. sport, accident, combat blast)\n* sinonasal condition (e.g. upper respiratory infection, rhinosinusitis, polyps)\n* neurological disorder (e.g. epilepsy, neurodegenerative disorder, narcolepsy)\n* serious mental illness (e.g. schizophrenia, bipolar, or other psychotic disorder)\n* suicidal ideation within the last month\n* current (≤6 months) heavy cigarette smoker (heavy defined as ≥ 10 pack-years)\n* oral\u002Fnasal steroids or other intranasal medications within the last month\n* immunomodulatory medications\n* pregnant or trying to become pregnant","18 Years","65 Years",{"count":55,"type":20},145,"INTERVENTIONAL",[58,59],"PHASE2","PHASE3","Persistent smell loss that can include diminished or distorted smell function is a common symptom of long COVID syndrome. There are limited treatment options for long COVID-related smell loss. This study aims to determine the efficacy of two at-home treatments, smell training and non-invasive trigeminal nerve stimulation. This study requires participants to conduct daily at-home treatment sessions, attend three in-person study visits at the MUSC Department of Psychiatry and Behavioral Sciences, and complete electronic questionnaires over the 12-week trial, and again at the six-month timepoint. Participants in this trial may benefit directly with an improvement in sense of smell. However, participation may also help society more generally, as this study will provide new information about long COVID-related smell loss and its treatment.",[62,27,63],"Smell Dysfunction","Long COVID",[65,66,67,68,69,70,71,72,73],"COVID-19","Parosmia","Hyposmia","Anosmia","Phantosmia","Dysosmia","Olfactory Training","Neuromodulation","Non-invasive Brain Stimulation","2026-04-01",{"date":76,"type":36},"2026-04-02",{"date":78,"type":36},"2023-10-02",{"date":80,"type":20},"2028-05-31",{"name":82,"class":43},"Medical University of South Carolina",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":92,"targetDuration":94,"studyType":21,"phases":4,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":83},"100551124","prospective-registery-of-smelltaste-clinic-earnosethroat-100551124","NCT06456008","Prospective Registery of Smell\u002FTaste Clinic Ear\u002FNose\u002FThroat","Prospective Registry of Outcome and Correlates of Chemosensory Dysfunction at the Smell & Taste Clinic of UZ Leuven","ProspeRo'Scent","Inclusion criteria:\n\n* The psychophysical testing as well as the questionnaires require a cooperative participant who can understand and follow instructions and communicate their choices.\n* Informed consent is necessary upon participation for prospective registry.\n\nThere are no exclusion criteria related to sex, gender, or ethnicity. There are no exclusion criteria related to medical history or prior treatments.",{"count":93,"type":20},500,"5 Years","Smell\u002Ftaste disorders are common conditions with a significant impact on quality of life. In September 2021, a specific consultation for patients with smell and taste disorders was initiated at the ENT-HNS (ear, nose, and throat, head and neck surgery) department of UZ Leuven, partly in light of post-COVID-19 related smell disorders.\n\nWith this observational ambidirectional study, the investigators aim to better map smell\u002Ftaste disorders in the Belgian\u002FFlemish population. Using standard-of-care diagnostic tests and structured questionnaires, the investigators strive to gain more insight into the severity, impact, and progression\u002Fprognosis of smell\u002Ftaste disorders.",[27,97,62,98],"Taste Disorders","Smell Disorder","2025-12-09",{"date":101,"type":36},"2025-12-18",{"date":103,"type":36},"2022-12-06",{"date":105,"type":20},"2035-12-31",{"name":107,"class":43},"Universitaire Ziekenhuizen KU Leuven",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":56,"phases":117,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":83},"100429235","phase-4-olfactory-outcomes-of-dupilumab-treatment-for-nasal-polyposis-100429235","NCT04869436","Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis","The 'Real World' Olfactory Outcomes Treating Nasal Polyposis With Dupilumab","Inclusion Criteria:\n\n* Patients older than 18 years old\n* Chronic rhinosinusitis with Nasal Polyps\n* Olfactory loss\n* Clinical indication for treatment with Dupilumab\n\nExclusion Criteria:\n\nPatients with olfactory loss from other causes such as:\n\n* Sinonasal malignancies\n* Trauma\n* Idiopathic olfactory loss\n* Use of cocaine\n* COVID-19 related olfactory loss\n* Pregnancy",{"count":116,"type":20},27,[118],"PHASE4","The study aims to investigate the olfactory TDI score (Threshold, Discrimination, Identification) using the Sniffin' sticks test for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) on dupilumab. Twenty-seven adult patients will be followed up during the treatment with dupilumab on three visits to the Otolaryngology Clinic (Baseline, 3 months and 6 months).\n\nThe primary endpoint will be the TDI score. Nasal polyp score, Quality of Olfactory Disorders - negative symptoms (QOD-NS symptom scores), SNOT-22 will be secondary endpoints.",[121,27],"Chronic Rhinosinusitis With Nasal Polyps","2024-12-18",{"date":124,"type":36},"2024-12-20",{"date":126,"type":36},"2021-07-19",{"date":128,"type":20},"2025-12-01",{"name":130,"class":43},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":15,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":56,"phases":141,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":83},"100562783","the-efficacy-of-olfactory-training-intervention-on-olfactory-and-other-non-motor-symptoms-in-pd-100562783","NCT06607653","The Efficacy of Olfactory Training Intervention on Olfactory and Other Non-motor Symptoms in PD","Inclusion Criteria:\n\n1. PD was diagnosed according to the criteria of Movement Disorders and Parkinson Disease Group of Chinese Society of Neurology of Chinese Medical Association.\n2. Olfactory score was 1 standard deviation lower than the corresponding age norm;\n3. no medication plan in the past four weeks or no change in medication plan in the past four weeks, which can be maintained until the end of the experiment; 4.40-75 years old, with normal vision, hearing and language understanding and expression ability;\n\n5.Good cooperation of patients\n\nExclusion Criteria:\n\n1. Parkinson\\'s syndrome and Parkinson\\'s plus syndrome caused by cerebrovascular disease, encephalitis, trauma, drugs, etc.;\n2. Neuropsychiatric diseases that may affect the sense of smell, such as depression, anxiety, schizophrenia, etc.;\n3. History of nasal disease or surgery, such as rhinitis, sinusitis, nasal septum deviation, etc. Upper respiratory tract infection in the past 3 weeks;\n4. Long-term smoking and occupations that inhale chemical irritants for a long time.","40 Years","75 Years",{"count":140,"type":20},40,[142],"NA","To explore the efficacy of olfactory training on olfactory and other non-motor symptoms in PD.",[145,27,71],"Parkinson Disease",[145,27,147],"Olfactory training","NOT_YET_RECRUITING","2024-09-20",{"date":151,"type":36},"2024-09-23",{"date":153,"type":20},"2024-09-25",{"date":155,"type":20},"2025-04-10",{"name":157,"class":43},"Anhui Medical University"]